Boston Scientific Corporation (BSX)
International Expansion Supports BSX Stock Amid Macroeconomic Woes
BSX's Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of gastrointestinal (GI) and pulmonary treatment options.
Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
BSX Stock Set to Gain From Agreement to Acquire Intera Oncology
Boston Scientific's new buyout is set to expand its interventional oncology offerings.
Why Is Boston Scientific (BSX) Up 7.5% Since Last Earnings Report?
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock?
BSX Stock Gains From Positive OPTION Trial Data for WATCHMAN FLX
Boston Scientific announces favorable OPTION trial results for its WATCHMAN FLX LAAC device. In terms of stroke risk reduction, WATCHMAN FLX is found to be superior to OAC therapy.
Reasons to Retain BSX Stock in Your Portfolio for Now
Investors remain optimistic about Boston Scientific due to its geographical expansions and impressive acquisitions.
Why Is Medical Device Giant Boston Scientific Stock Trading Higher On Monday?
On Saturday, Boston Scientific Corporation BSX unveiled three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device.
Boston Scientific Corporation (BSX) UBS Global Healthcare Conference (Transcript)
Boston Scientific Corporation (NYSE:BSX ) UBS Global Healthcare Conference November 12, 2024 10:15 AM ET Company Participants Jonathan Monson - Senior Vice President, Investor Relations Nick Spadea-Anello - VP & GM of Interventional Cardiology Conference Call Participants Danielle Antalffy - UBS Danielle Antalffy So good morning, everyone. Thanks so much for joining us.
Boston Scientific Corporation (BSX) Business Update Earnings Call Transcript
Boston Scientific Corporation (NYSE:BSX ) Business Update Earnings Conference Call October 30, 2024 4:00 PM ET Company Participants Jonathan Monson - Senior Vice President of Investor Relations Joseph Fitzgerald - Executive Vice President and Group President, Cardiology Lance Bates - Senior Vice President and President Janar Sathananthan - Chief Medical Officer Kenneth Stein - Chief Medical Officer Conference Call Participants Operator Good day, and welcome to the Boston Scientific Cardiology Business Update. [Operator Instructions] Please note, this event is being recorded.
Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Boston Scientific Stock Gains From Market Expansion, Innovation
BSX's Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of gastrointestinal and pulmonary treatment options.
Why The Fundamentals Make Me Bullish On Boston Scientific
Medical devices maker Boston Scientific should continue to grow profitably through the next several years. Backing that bullishness is its history, good margins, pipeline, capital allocation, and more. While all other Seeking Alpha analysts have rated it a Hold this year, I have a Buy rating and expect the price to grow nearly 15% in the coming year.
